Dataset Information


Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety.



Continuous delivery of levodopa-carbidopa intestinal gel (LCIG) provides stable plasma levodopa concentrations and reduces motor fluctuations in advanced Parkinson's disease (PD) patients.


To compare the effectiveness and safety of LCIG monotherapy vs polytherapy in patients in the GLORIA registry.


This was a post hoc analysis of a 24-month, multinational observational registry where advanced PD patients with persistent motor complications received LCIG (with adjunctive PD treatment, as necessary). Patients were categorized retrospectively into three stable treatment groups: LCIG monotherapy, LCIG in combination with oral levodopa only ("levodopa monotherapy" [including nighttime oral levodopa]), or LCIG in combination with any other antiparkinsonian medication ("LCIG polytherapy").


Of 356 patients, 208 were on stable regimens (LCIG monotherapy n?=?80; levodopa monotherapy n?=?47; LCIG polytherapy n?=?81). Baseline characteristics were similar across groups. LCIG monotherapy showed significant improvements until month 18 in activities of daily living and quality of life, and until month 24 for Unified Parkinson's Disease Rating Scale (UPDRS) motor examination (p?ConclusionsThese data demonstrate that LCIG monotherapy is an effective treatment option in appropriate advanced PD patients; however, definitive baseline clinical predictors identifying patients who can discontinue concomitant oral therapy have not yet been defined.

PROVIDER: S-EPMC6700622 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC8302193 | BioStudies
| S-EPMC8453961 | BioStudies
| S-EPMC8699449 | BioStudies
| S-EPMC5724683 | BioStudies
| S-EPMC5504221 | BioStudies
2015-01-01 | S-EPMC4559582 | BioStudies
| S-EPMC5516619 | BioStudies
| S-EPMC6801178 | BioStudies
| S-EPMC9292774 | BioStudies
| S-EPMC7604637 | BioStudies